RY 175.42 -0.2162% SHOP 157.15 -0.958% TD 79.04 0.0886% ENB 61.42 0.7711% BN 86.09 -0.3934% TRI 231.36 0.0562% CNQ 47.61 0.8046% CP 105.71 -1.4083% CNR 154.12 -1.2811% BMO 133.23 -0.2396% BNS 77.09 -3.3839% CSU 4762.73 -0.5755% CM 89.48 -0.633% MFC 45.25 -0.2645% ATD 82.67 -0.4336% NGT 58.69 2.2296% TRP 68.72 0.7034% SU 54.51 -1.1067% WCN 268.52 0.1492% L 186.4 1.1998%
Last update at 2024-12-03T15:42:00Z
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Income before tax | -4.46100M | -9.25392M | 0.42M | -6.95222M | -9.13777M |
| Minority interest | - | - | - | - | - |
| Net income | -4.46100M | -9.66321M | 23.48M | -6.95222M | -9.13777M |
| Selling general administrative | 7.40M | 6.96M | 4.80M | 8.64M | 11.85M |
| Selling and marketing expenses | 8.17M | 6.52M | 1.93M | 7.79M | 14.95M |
| Gross profit | 14.36M | 7.49M | 9.70M | 12.49M | 21.82M |
| Reconciled depreciation | 0.97M | 1.03M | 0.70M | 1.21M | 0.63M |
| Ebit | -4.52850M | -9.14233M | 0.84M | -5.64259M | -8.24863M |
| Ebitda | -3.55913M | -8.10952M | 1.54M | -4.88597M | -7.61874M |
| Depreciation and amortization | 0.97M | 1.03M | 0.70M | 0.76M | 0.63M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -4.52850M | -9.14233M | 0.84M | -6.09207M | -8.24863M |
| Other operating expenses | 31.12M | 27.29M | 18.72M | 31.89M | 42.25M |
| Interest expense | - | 0.11M | 0.42M | 0.86M | 0.89M |
| Tax provision | - | - | - | - | - |
| Interest income | - | - | - | - | - |
| Net interest income | 0.07M | -0.11159M | -0.41938M | -0.86016M | -0.88914M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.80M | 0.41M | -23.05794M | 1.00M | 0.46M |
| Total revenue | 26.60M | 18.15M | 19.56M | 25.80M | 34.00M |
| Total operating expenses | 18.89M | 16.64M | 8.86M | 18.58M | 30.07M |
| Cost of revenue | 12.23M | 10.65M | 9.86M | 13.31M | 12.18M |
| Total other income expense net | 0.07M | -0.11159M | -0.41938M | -0.86016M | -0.88914M |
| Discontinued operations | - | -0.40930M | 23.06M | 0.87M | 0.87M |
| Net income from continuing ops | -4.46100M | -9.25392M | 0.42M | -6.95222M | -9.13777M |
| Net income applicable to common shares | - | -9.66321M | 23.48M | -6.95222M | -9.13777M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Total assets | 24.90M | 30.38M | 40.58M | 34.70M | 39.61M |
| Intangible assets | 1.79M | 1.28M | 0.90M | 2.15M | 2.36M |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.39M | - | - | - | 0.12M |
| Total liab | 6.11M | 6.15M | 7.21M | 25.59M | 24.68M |
| Total stockholder equity | 18.79M | 24.23M | 33.37M | 9.11M | 14.93M |
| Deferred long term liab | - | 0.29M | 0.38M | 0.51M | 0.61M |
| Other current liab | 0.67M | 0.21M | 0.41M | 0.50M | 0.46M |
| Common stock | 42.77M | 43.84M | 44.68M | 44.61M | 44.61M |
| Capital stock | 42.77M | 43.84M | 44.68M | 44.61M | 44.61M |
| Retained earnings | -38.36628M | -33.90528M | -24.24207M | -47.71898M | -40.76675M |
| Other liab | - | 0.05M | 0.16M | 0.29M | 0.44M |
| Good will | - | - | - | 13.02M | 12.92M |
| Other assets | - | 0.29M | 0.51M | 0.54M | 0.65M |
| Cash | 8.79M | 14.06M | 22.95M | 3.51M | 9.58M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 5.19M | 4.54M | 5.00M | 22.64M | 17.94M |
| Current deferred revenue | 0.08M | - | - | - | - |
| Net debt | -7.23219M | - | - | 14.22M | 8.52M |
| Short term debt | 0.64M | - | - | - | 11.80M |
| Short long term debt | - | - | - | 17.72M | 11.80M |
| Short long term debt total | 1.56M | - | - | - | - |
| Other stockholder equity | 11.44M | 3.01M | 1.11M | 0.57M | 0.37M |
| Property plant equipment | - | 1.87M | 2.11M | 4.64M | 1.89M |
| Total current assets | 21.29M | 27.23M | 37.44M | 14.85M | 22.39M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 23.24M | 32.85M | -5.55766M | 0.26M |
| Short term investments | - | - | - | - | - |
| Net receivables | 6.16M | 4.73M | 6.40M | 3.33M | 3.64M |
| Long term debt | - | - | - | - | 6.29M |
| Inventory | 5.94M | 4.97M | 4.70M | 7.20M | 8.58M |
| Accounts payable | 3.80M | 3.72M | 4.04M | 3.90M | 5.68M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 2.95M | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.14M | - | 0.14M | 0.04M | 0.04M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 3.61M | 3.15M | 3.14M | 19.85M | 17.21M |
| Capital lease obligations | 1.56M | 2.17M | 2.59M | 3.18M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Investments | -1.45172M | -0.84302M | -0.27853M | -0.37041M | -7.09569M |
| Change to liabilities | - | -0.69242M | 0.02M | -1.64127M | 1.29M |
| Total cashflows from investing activities | - | 0.32M | 36.37M | -0.37041M | -7.09569M |
| Net borrowings | - | -0.58518M | -7.96614M | -1.07035M | 6.88M |
| Total cash from financing activities | -2.15605M | -2.18614M | -8.25217M | -1.75277M | 13.98M |
| Change to operating activities | - | -1.16968M | -0.07194M | -0.20344M | 0.58M |
| Net income | -4.46100M | -9.25392M | 0.42M | -6.95222M | -9.13777M |
| Change in cash | -5.26698M | -8.88529M | 19.44M | -6.06816M | 4.09M |
| Begin period cash flow | 14.06M | 22.95M | 3.51M | 9.58M | 5.48M |
| End period cash flow | 8.79M | 14.06M | 22.95M | 3.51M | 9.58M |
| Total cash from operating activities | -3.18401M | -7.99357M | 0.62M | -4.02544M | -2.82548M |
| Issuance of capital stock | - | - | - | 0.00000M | 5.50M |
| Depreciation | 0.97M | 1.03M | 0.70M | 1.21M | 0.63M |
| Other cashflows from investing activities | - | 1.30M | 36.55M | -0.16436M | -0.00057M |
| Dividends paid | - | 1.60M | 0.00000M | 0.00000M | 0.00000M |
| Change to inventory | -1.04360M | -0.06337M | 2.16M | 1.44M | -2.14411M |
| Change to account receivables | -1.47001M | 1.84M | -3.19397M | 0.33M | 3.35M |
| Sale purchase of stock | -1.47229M | -1.72695M | 0.00000M | - | - |
| Other cashflows from financing activities | -1.45172M | 3.33M | 0.71M | 0.23M | 9.89M |
| Change to netincome | - | 0.34M | -22.78912M | 2.25M | 2.61M |
| Capital expenditures | 1.32M | 1.08M | 0.18M | 0.37M | 1.28M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -0.31775M | -0.08338M | -1.08121M | -0.07509M | 3.08M |
| Stock based compensation | 0.56M | 0.21M | 0.16M | 0.72M | 1.72M |
| Other non cash items | 0.07M | 0.11M | 0.42M | 0.86M | 0.89M |
| Free cash flow | -4.50052M | -9.07532M | 0.44M | -4.39653M | -4.10906M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| COV Covalon Technologies Ltd. |
0.12 3.21% | 3.86 | - | - | 3.38 | 4.55 | 3.09 | 2136.68 |
| NGEN NervGen Pharma Corp |
0.12 4.17% | 3.00 | - | - | - | 14.75 | -4.5367 | |
| ARCH Arch Biopartners Inc |
0.01 0.51% | 1.96 | - | - | 93.45 | - | 53.05 | -97.5918 |
| MIR MedMira Inc |
-0.005 6.25% | 0.07 | - | - | 164.76 | - | 180.27 | -80.0318 |
| NRX NurExone Biologic Inc. |
- -% | 0.73 | - | - | - | 12.86 | -7.2365 |
Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company's platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity. It also offers medical coating platform, a process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. In addition, the company provides wound care dressings; surgical and peri-operative; and infection management products. It offers its products under the Covalon brand name through third-party distribution networks and company's direct sales force. The company serves hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians' offices. Covalon Technologies Ltd. is headquartered in Mississauga, Canada.
1660 Tech Avenue, Mississauga, ON, Canada, L4W 5S7
| Name | Title | Year Born |
|---|---|---|
| Mr. Brian E. Pedlar | Pres, CEO & Director | NA |
| Simon Smith | Chief Exec. Officer of Covalon Technologies (Europe) Ltd. | NA |
| Gerry Arambula | Pres of Covalon Technologies AG Ltd. | NA |
| Dr. Valerio DiTizio | Co-Founder, Chief Scientific Officer & VP | 1968 |
| Mr. Jason F. Gorel | Interim Chief Financial Officer | NA |
| Ms. Elaine Zhang | VP of Operations | NA |
| Mr. Ron Hebert | Sr. VP of Marketing | NA |
| Mr. Greg Leszczynski | VP of HR | NA |
| Mr. Mark Doolittle | Sr. VP of Commercial Sales | NA |
| Mr. Hamed Abbasian | VP of Bus. Devel. | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...